Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 pa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Dougherty, Brian A., Lai, Zhongwu, Hodgson, Darren R., Orr, Maria C.M., Hawryluk, Matthew, Sun, James, Yelensky, Roman, Spencer, Stuart K., Robertson, Jane D., Ho, Tony W., Fielding, Anitra, Ledermann, Jonathan A., Barrett, J. Carl
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Priority Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546431/
https://ncbi.nlm.nih.gov/pubmed/28525389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17613
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller